cBAT - CBAT

CBAK Energy Tech (NASDAQ:CBAT) Bolsa

CBAK Energy Tech

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

CBAK Energy Technology, Inc. - Common Stock

CBAK Energy Technology Inc

WIIM

TSLA

Tesla shares are trading higher after Elon Musk, at the Qatar Economic Forum, said the company has "Already turned around." Musk also announced that he remains committed to being the company's CEO for the next five years.

JMP Securities analyst Patrick Walravens reiterates Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Market Outperform and maintains $201 price target.

News

Price Target

Reiteration

Analyst Ratings

SNOW

JMP Securities Reiterates Market Outperform on Snowflake, Maintains $201 Price Target

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $169 to $84.

SRPT

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $84

<a href="https://www.hp.com/us-en/newsroom/blogs/2025/HP-Tecan-Expand-Collaboration.html">https://www.hp.com/us-en/newsroom/blogs/2025/HP-Tecan-Expand-Collaboration.html</a>
HP is teaming up with Tecan, a global leader in laboratory automation for life sciences and diagnostics, to launch the Duo Digital DispenserTM, a new solution designed to simplify how researchers isolate individual cells and develop new therapeutics. Powered by HP's inkjet technology, Duo combines the capabilities of the <a href="https://www.tecan.com/simplify-your-dose-response-curve-with-d300e?&amp;utm_term=tecan%20d300e&amp;utm_campaign=SO-FluentControl&amp;utm_source=adwords&amp;utm_medium=ppc&amp;hsa_net=adwords&amp;hsa_tgt=kwd-761482067978&amp;hsa_ad=646626667156&amp;hsa_acc=9279258943&amp;hsa_grp=145508072373&amp;hsa_mt=e&amp;hsa_cam=19637595011&amp;hsa_kw=tecan%20d300e&amp;hsa_ver=3&amp;hsa_src=g&amp;gad=1&amp;gclid=CjwKCAjw3oqoBhAjEiwA_UaLtgJoulFmUVfDxcfU0k_LHgLgwAFPDZfvoZk7ht9jVtWOzL-51hgTERoCGvQQAvD_BwE">D300e Digital Dispenser</a> and the <a href="https://www.tecan.com/uno">Uno Single Cell DispenserTM</a>, delivering a major advancement in speed and precision for cancer research and other critical applications in life sciences. &nbsp; By combining single-cell and reagent dispensing into one system, the new instrument significantly improves lab efficiency, reducing sample processing time, increasing reproducibility, and cutting down on labware waste and reagent use. Duo is 40 times faster than conventional methods1 for drug discovery, reducing dosing time from 10 minutes to 15 seconds. Cell dispensing with Duo enables researchers to isolate single cells in less than 5 minutes compared to 1 hour when using traditional cell isolation technology2. The instrument features a single-use disposable component that simplifies setup, minimizes contamination risk, and enables experimental reproducibility. &nbsp; In addition to dispensing cells, Duo enables researchers to dispense reagents without the use of surfactants. This innovation is especially important for scientists developing advanced biologic therapeutics, which can be particularly sensitive to surfactants.

HP And Tecan Expand Strategic Collaboration To Unveil New Dual Use Single Cell And Reagent Dispenser For Life Science And Pharma Research

D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares are ripping higher in early trading Tuesday after the company announced the general availability of its <a href="https://www.benzinga.com/pressreleases/25/05/b45514131/d-wave-announces-general-availability-of-advantage2-quantum-computer-its-most-advanced-and-perform">most advanced quantum computer</a>.
What Happened: Quantum computing company D-Wave announced the availability of its commercial-grade Advantage2 system, built to address real-world use cases in optimization, materials simulation and AI.
The company said customers can now access the Advantage2 system through its D-Wave&#8217;s Leap real-time quantum cloud service. Currently available in more than 40 countries, the system offers sub-second response times and SOC 2 Type 2 compliance to meet enterprise needs and security requirements. Advantage2 is also available for hyperscalers to purchase for on-premises ownership. 
&#8220;Today marks a significant milestone not just for D-Wave, but for the quantum computing industry as a whole, as we bring to market our sixth-generation quantum computer, a system so powerful that it can solve hard problems outside the reach of one of the world&#8217;s largest exascale GPU-based classical supercomputers,&#8221; said Alan Baratz, CEO of D-Wave. 
&#8220;It&#8217;s an engineering marvel, with substantial technical advancements that highlight D-Wave&#8217;s progress in scaling quantum technology to meet industry demands for growing computational processing power while maintaining energy efficiency.&#8221;
D-Wave said its latest quantum processor offers several advantages versus the prior generation, including increased qubit connectivity, higher energy scale and greater coherence. The system also enables coherent quantum annealing at scale and hybrid solver integration.
Related Link: <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45503887/quantum-vs-ai-nvidias-next-big-bet-could-supercharge-these-2-etfs">Quantum Vs AI: Nvidia&#8217;s Next Big Bet Could Supercharge These 2 ETFs</a>
<h3 class="wp-block-heading">How To Buy QBTS Stock</h3>
By now you're likely curious about how to participate in the market for D-Wave Quantum &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of D-Wave Quantum, which is trading at $13.15 as of publishing time, $100 would buy you 7.6 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
QBTS Price Action: <a href="http://benzinga.com/quote/qbts">D-Wave Quantum shares</a> are up nearly 975% over a one-year period. The quantum stock was up 19.5% at $15.73 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of D-Wave Quantum.

Movers

QBTS

D-Wave Quantum Stock Is Surging Tuesday: Here's Why

<a href="https://www.youtube.com/watch?v=JaRwKHdZikA" title="https://www.youtube.com/watch?v=JaRwKHdZikA">https://www.youtube.com/watch?v=JaRwKHdZikA</a>

Management

Global

At The Qatar Economic Forum, Elon Musk Says Tesla Has "Already Turned Around", Europe Weakest Market, Strong Everywhere Else; Still Committed To Be Tesla CEO In 5 Years Time, Unless I Die; Having Reasonable Control Of Tesla Is Most Important Factor To Remain CEO

JP Morgan analyst Doug Anmuth maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and raises the price target from $92 to $105.

UBER

JP Morgan Maintains Overweight on Uber Technologies, Raises Price Target to $105

<ul>
<li>UNH</li>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>RDDT</li>
<li>BULL</li>
<li>QBTS</li>
<li>NBIS</li>
<li>GOOGL</li>
<li>PLTR</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

BULL

GOOGL

NBIS

NVDA

PLTR

RDDT

Top 10 Trending Stocks On WallStreetBets As Of May 20, 2025 (Via Swaggy Stocks)

Morgan Stanley analyst Ronald Kamdem maintains Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) with a Equal-Weight and raises the price target from $25 to $26.

SNDA

Morgan Stanley Maintains Equal-Weight on Sonida Senior Living, Raises Price Target to $26

JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) with a Market Outperform and lowers the price target from $10 to $6.

PRME

JMP Securities Maintains Market Outperform on Prime Medicine, Lowers Price Target to $6

Morgan Stanley analyst Ronald Kamdem maintains American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Overweight and raises the price target from $37 to $45.

Morgan Stanley Maintains Overweight on American Healthcare REIT, Raises Price Target to $45

Morgan Stanley analyst Meta Marshall maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Equal-Weight and raises the price target from $40 to $62.

PSTG

Morgan Stanley Maintains Equal-Weight on Pure Storage, Raises Price Target to $62

Jones Trading analyst Soumit Roy initiates coverage on ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy rating and announces Price Target of $40.

Initiation

AVBP

Jones Trading Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $40

Morgan Stanley analyst Meta Marshall maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $84 to $106.

NTAP

Morgan Stanley Maintains Equal-Weight on NetApp, Raises Price Target to $106

Basel Medical Group Ltd (NASDAQ:<a href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>), today announced that its subsidiary has been awarded a significant contract worth S$375 million by Pancare Technology International (HK) Limited to supply essential healthcare products in Asia-Pacific over the next five years until October 31, 2029. This milestone underscores the Company's commitment to delivering high-quality medical solutions and strengthening its global presence in the healthcare sector.
As part of the Company's strategic vision, the Company will be accelerating the integration of AI-powered technologies into its healthcare supply chain operations. This initiative aims to enhance efficiency, optimize logistics, and to ensure the timely delivery of critical medical products to healthcare providers across Asia-Pacific and beyond.

Contracts

BMGL

Basel Medical Group Subsidiary Bags S$375M Contract From Pancare Technology International To Supply Essential Healthcare Products In Asia-Pacific Until October 31, 2029

Morgan Stanley analyst Meta Marshall maintains Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) with a Overweight and raises the price target from $75 to $90.

NTNX

Morgan Stanley Maintains Overweight on Nutanix, Raises Price Target to $90

Morgan Stanley analyst Meta Marshall maintains Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) with a Equal-Weight and raises the price target from $14 to $22.

Morgan Stanley Maintains Equal-Weight on Hewlett Packard, Raises Price Target to $22

Jefferies analyst Julien Dumoulin-Smith upgrades Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) from Hold to Buy and raises the price target from $70 to $71.

Upgrades

Jefferies Upgrades Alliant Energy to Buy, Raises Price Target to $71

As <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening
Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026
Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> and to <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">Breakthrough Therapy</a> designation in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 20, 2025 / <a href="https://pr.report/als3">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/als5">Napo Pharmaceuticals, Inc.</a> (Napo) and <a href="https://pr.report/als6">Napo Therapeutics S.p.A.</a> today announced that the first patient has been randomized in Napo's randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of the novel crofelemer oral powder for solution formulation in pediatric patients with intestinal failure due to the ultrarare disease MVID.
Patients with MVID suffer from devastating diarrhea and dehydration caused by this debilitating, lifelong condition. These pediatric patients often require lifelong and life-sustaining total parenteral nutrition (TPN) with additional supplemental intravenous (IV) fluids, termed total parenteral support, which is the standard of care for MVID, for up to 7 days a week greater than 50% of the time each day to provide adequate nutrient and electrolyte support. While crucial for MVID patients, TPN carries a significant risk of morbidity and mortality due to infections, metabolic complications, liver and/or kidney disease, and a risk of neurodevelopmental delay. There are currently no approved drug treatments for MVID.
Based on the initial proof-of-concept findings presented last month at the 11th Annual ELITE PED-GI Congress, crofelemer's novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients, as evidenced by the reductions in total parenteral support and potential to improve the quality of life of MVID patients.

JAGX

Jaguar Health Says First Patient Randomized In Napo's Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of Crofelemer In Pediatric Patients With MVID

Morgan Stanley analyst Kristine Liwag maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $390 to $415.

Morgan Stanley Maintains Overweight on RBC Bearings, Raises Price Target to $415

Press Releases

General

CBAK Energy's 32140 Cells Capture 19% of Global Market Share, Report Shows

Commodities

CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong

CBAK Energy to Report fourth quarter & full year 2024 Unaudited Financial Results on Monday, March 17, 2025

Earnings

CBAK Energy Reports Full Year of 2024 Unaudited Financial Results

Kandi and CBAK Announce Strategic Partnership to Launch U.S. Lithium Battery Facilities in Phases

CBAK Partners with Kandi to Localize Lithium Battery Facilities in the U.S. in Phases

CBAK Energy Captures 14.6% Share of 32140 Cylindrical Cell Market in Q1 2025

CBAK Energy to Participate in Shenzhen International Battery Technology Conference & Expo on Tuesday, May 15, 2025

CBAK Energy to Report First Quarter 2025 Unaudited Financial Results on Monday, May 19, 2025

CBAK Energy Reports First Quater 2025 Unaudited Financial Results

CBAT

KNDI

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

CBAK Energy Tech

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL